Aktienanalyse zu Soleno Therapeutics Inc (SLNO)SLNOSoleno Therapeutics Inc

Soleno Therapeutics, Inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its first commercial product, VYKAT XR (diazoxide choline) extended-release tablets, is a once-daily oral treatment for hyperphagia in adults and children four years of age and older with Prader-Willi syndrome (PWS). VYKAT XR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. The KATP channels play a central role in the regulation of a number of physiological processes which may otherwise be dysregulated, contributing to the pathophysiology of several diseases. In the context of the underlying genetic or structural defects in PWS, these pathophysiological processes may cumulatively contribute to increases in appetite and aggressive food seeking, lack of satiety, accumulation of excess body fat and the establishment and perpetuation of the obese state. PWS is a rare, complex genetic neurobehavioral/metabolic disorder. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

SLNO is not a good buy right now for a beginner-focused, long-term investor with $50,000-$100,000 to deploy. The stock is trading essentially at the $53 acquisition price, so the upside is capped and the expected return from here is minimal. Since the user is unwilling to wait for a better entry, this is still not attractive because the current price already reflects the deal value. Best direct call: do not buy SLNO now.

1 analysts cover SLNO: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 110.50.